Current Report Filing (8-k)
November 13 2020 - 6:08AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported) November 13, 2020
Cassava
Sciences, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-29959
|
|
91-1911336
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
Number)
|
7801
N Capital of Texas Highway, Suite 260
Austin,
Texas 78731
(Address
of principal executive offices, including zip code)
(512)
501-2444
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2 below):
[ ]
|
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communication pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communication pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, $0.001 par value
|
|
SAVA
|
|
NASDAQ
Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. [ ]
Item
8.01. Other Events.
This
Form 8-K is being filed by Cassava Sciences, Inc. (the “Company”) to correct statements regarding duration of, and
clarify statements regarding scope of, patent protection in the Company’s Annual Report on Form 10-K for the year ended
December 31, 2019 and subsequent Quarterly Reports on Form 10-Q for the quarters ended March 31, June 30 and September 30, 2020,
respectively. The Company’s patent protection with respect to sumifilam (formerly known as PTI-125) and use of sumifilam
for Alzheimer’s disease and other neurodegenerative disease currently runs through 2033 and includes six issued patents
and related patent filings and applications. In addition, the Company has patent protection with respect to sumifilam for use
in treating certain cancers that runs through 2034. The Company has no patents or patent applications with respect to SavaDx,
which is protected by trade secrets, know-how and other proprietary rights technology.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed
on its behalf by the undersigned thereunto duly authorized.
|
CASSAVA
SCIENCES, INC.
|
|
a
Delaware corporation
|
|
|
|
Date: November
13, 2020
|
|
|
|
By:
|
/s/
ERIC J. SCHOEN
|
|
|
Eric
J. Schoen
|
|
|
Chief
Financial Officer
|
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Sep 2023 to Sep 2024